iFCR一线治疗CLL/SLL的长期结局及MRD作用
该回顾性研究分析34例初治CLL/SLL患者接受iFCR方案的长期结局与MRD价值,中位随访60.2个月,5年PFS率58.6%、OS率94.4%。IGHV无突变及TP53异常为PFS不利因素;联合治疗结束2个月后PB-uMRD4者CR率更高且uMRD维持更久,动态监测PB-MRD及2年BM-MRD可指导伊布替尼维持策略调整。
要点
- IGHV无突变及TP53异常是iFCR一线治疗CLL/SLL的PFS不利因素
- 联合治疗结束2个月后PB-uMRD4者CR率更高且uMRD维持更久
- 动态监测PB-MRD有助于发现MRD复阳和疾病进展
核心结论
- IGHV无突变及TP53异常是接受iFCR一线治疗的CLL/SLL患者PFS的不利因素。
- 联合治疗结束2个月后达PB-uMRD4患者有望保持长时间PB-uMRD4。
- 伴有复杂核型、del(17p)、TP53突变等高危因素者达到uMRD并停药的可能性小。
- 根据治疗2年时的BM-MRD水平调整伊布替尼维持策略可行,动态监测PB-MRD有助于发现MRD复阳和疾病进展。
研究设计与样本
- 回顾性收集2019年2月至2025年6月南京医科大学第一附属医院血液科接受iFCR方案治疗的34例初治CLL/SLL患者数据。
- 分析FCM及NGS检测的MRD数据,并与疗效评估、PFS、OS等指标综合分析。
- uMRD4定义为经FCM检测MRD<10(-4)。
- 根据PB-MRD动力学分为持续uMRD4组(13例)、MRD复阳组(4例)和MRD持续阳性组(7例)。
主要发现
- 中位随访60.2(95% CI:53.9~66.5)个月,中位PFS期和OS期均未达到。
- 5年PFS率和OS率分别为58.6%(95% CI:35.6%~96.6%)和94.4%(95% CI:84.4%~100%)。
- IGHV突变患者中位PFS期未达到,IGHV无突变患者为59.3个月(P=0.019)。
- TP53无异常患者中位PFS期未达到,TP53异常患者为38.6个月(P=0.011)。
- 联合治疗结束2个月后PB-uMRD4者CR率73.3%,PB-MRD阳性者20.0%(P=0.015)。
关键数值与推荐
- PB-uMRD4持续时间36.3±16.2个月,PB-MRD阳性者4.6±4.7个月(P<0.001)。
- FCM检测PB-MRD与BM-MRD一致性P<0.001、r=0.739;NGS检测一致性P<0.001、r=0.869。
- FCM与NGS检测PB-MRD一致性P=0.003、r=0.439,优于BM-MRD的P=0.033、r=0.299。
- iFCR治疗至2年时根据BM-MRD水平主动停药9例或继续维持19例,进展分别1例(11.1%)和7例(36.8%)。
- 持续uMRD4组较MRD持续阳性组复杂核型(7.7%对57.1%)、del(17p)(0对42.9%)、TP53突变(0对42.9%)比例低,P=0.031。
临床怎么用
- 对初治CLL/SLL患者可评估IGHV突变状态及TP53异常以判断iFCR方案PFS预后。
- 联合治疗结束2个月后检测PB-MRD,达PB-uMRD4者预期CR率更高且uMRD维持更久。
- iFCR治疗2年时根据BM-MRD水平决定主动停药或继续伊布替尼维持。
- 长期随访中动态监测PB-MRD以及时发现MRD复阳和疾病进展。
局限性
- 本研究为单中心回顾性研究,样本量34例。
- 随访时间有限,中位PFS期和OS期均未达到。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: This study aimed to investigate the clinical significance of measurable residual disease (MRD) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with ibrutinib plus fludarabine, cyclophosphamide, and rituximab (iFCR) regimen. Methods: Data of 34 patients with treatment-naive CLL/SLL treated with the iFCR regimen in the Department of Hematology of The First Affiliated Hospital of Nanjing Medical University from February 2019 to June 2025 were retrospectively collected and comprehensively analyzed. Data included MRD detected with flow cytometry (FCM) and NGS, efficacy evaluation, progression-free survival (PFS), and overall survival (OS). UMRD4 was defined as MRD of <10(-4) detected with FCM. According to peripheral blood MRD (PB-MRD) kinetics, patients were categorized into three groups: sustained uMRD4 (n=13), MRD relapse (n=4), and sustained MRD positive (n=7) . Results: Median follow-up was 60.2 (95% CI: 53.9-66.5) months, and the median PFS and median OS times were not reached. The 5-year PFS and OS rates were 58.6% (95% CI: 35.6% -96.6% ) and 94.4% (95% CI: 84.4% -100% ), respectively. Compared with patients with unmutated immunoglobulin heavy chain variable (IGHV) and TP53 aberration, patients demonstrating mutated IGHV (median PFS time: not reached vs 59.3 months, P= 0.019) and the absence of TP53 aberration (median PFS time: not reached vs 38.6 months, P=0.011) were associated with a longer PFS. After 2 months of combination therapy completion, patients with PB-uMRD4 achieved a higher rate of complete response (CR) compared with those with positive PB-MRD (73.3% vs 20.0%, P=0.015) and demonstrated a longer PB-uMRD4 duration during long-term follow-up (36.3±16.2 months vs 4.6±4.7 months, P<0.001). A good concordance was observed between PB-MRD and bone marrow MRD (BM-MRD) detected with FCM (P<0.001, r=0.739) and NGS (P<0.001, r=0.869). Further, the concordance of PB-MRD detection (P=0.003, r=0.439) between FCM and NGS was superior to that of BM-MRD (P=0.033, r=0.299). Treatment was either actively discontinued (those achieving uMRD4) or continued (those with detectable MRD) according to the BM-MRD level after 2 years of iFCR treatment. Furthermore, disease progression occurred in 1 (1/9, 11.1% ) patient who discontinued therapy and 7 (7/19, 36.8% ) patients who continued treatment. Among them, 7 patients who actively discontinued treatment and kept PB-uMRD4 and CR demonstrated no del (17p), del (11q), and TP53 mutations. The proportion of patients with complex karyotypes (7.7% vs 57.1%, P=0.031), del (17p) (0 vs 42.9%, P=0.031), and TP53 mutations (0 vs 42.9%, P=0.031) was lower in the sustained uMRD4 group compared with the sustained MRD-positive group. Conclusion: Unmutated IGHV and TP53 aberration remained adverse factors for PFS in patients with CLL/SLL who received the first-line iFCR regimen. After 2 months of combination therapy completion, patients with PB-uMRD4 were more likely to maintain PB-uMRD4 for an extended period, whereas patients with high-risk factors, including complex karyotype, del (17p), and TP53 mutation, were less likely to achieve uMRD and discontinue treatment. Furthermore, the ibrutinib maintenance strategy can be adjusted based on the BM-MRD level at 2 years. Monitoring PB-MRD dynamically was crucial in detecting MRD conversion and progression. 目的: 探索可检测残留病(MRD)在iFCR(伊布替尼联合氟达拉滨、环磷酰胺、利妥昔单抗)方案治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(CLL/SLL)中的临床价值。 方法: 回顾性收集并分析2019年2月至2025年6月在南京医科大学第一附属医院血液科接受iFCR方案治疗的34例初治CLL/SLL患者的治疗过程及随访阶段以流式细胞术(FCM)及二代测序(NGS)检测的MRD数据,并与疗效评估、无进展生存(PFS)、总生存(OS)等指标综合分析。uMRD4定义为经FCM检测MRD<10(-4)。根据外周血MRD(PB-MRD)动力学将患者分为持续uMRD4组(13例)、MRD复阳组(4例)和MRD持续阳性组(7例)。 结果: 中位随访时间60.2(95% CI:53.9~66.5)个月,患者总体中位PFS期和OS期均未达到。5年PFS率和OS率分别为58.6%(95% CI:35.6%~96.6%)和94.4%(95% CI:84.4%~100%)。与免疫球蛋白重链可变区(IGHV)无突变和TP53异常的患者相比,IGHV突变(中位PFS期:未达到对59.3个月,P=0.019)和TP53无异常(中位PFS期:未达到对38.6个月,P=0.011)的患者PFS期更长。联合治疗结束2个月后达PB-uMRD4患者与PB-MRD阳性患者相比获得完全缓解(CR)率更高(73.3%对20.0%,P=0.015),且长期随访中PB-uMRD4持续时间更长[(36.3±16.2)个月对(4.6±4.7)个月,P<0.001]。经FCM(P<0.001,r=0.739)和NGS(P<0.001,r=0.869)检测的PB-MRD与骨髓MRD(BM-MRD)具有较好的一致性,而在同一样本中,FCM和NGS检测PB-MRD的一致性(P=0.003,r=0.439)优于BM-MRD(P=0.033,r=0.299)。患者接受iFCR方案治疗至2年时根据BM-MRD水平选择主动停药(达uMRD4者,9例)或继续维持(MRD阳性,19例),至末次随访时分别有1例(1/9,11.1%)和7例(7/19,36.8%)患者出现疾病进展,而其中7例主动停药保持PB-uMRD4且CR状态者均不合并del(17p)、del(11q)和TP53突变。持续uMRD4组较MRD持续阳性组复杂核型(7.7%对57.1%,P=0.031)、del(17p)(0对42.9%,P=0.031)、TP53突变(0对42.9%,P=0.031)患者比例低。 结论: IGHV无突变及TP53异常是接受iFCR方案一线治疗的CLL/SLL患者PFS的不利因素。联合治疗结束2个月后达PB-uMRD4患者有望保持长时间PB-uMRD4,而伴有复杂核型、del(17p)、TP53突变等高危因素者达到uMRD并停药的可能性小;根据治疗2年内的BM-MRD水平调整伊布替尼维持策略可行,动态监测PB-MRD有助于发现MRD复阳和疾病进展。.
引用
- Liu M, Sha YQ, Qin SC, et al. [Long-term outcomes of first-line iFCR regimen in chronic lymphocytic leukemia/small lymphocytic lymphoma and the role of MRD]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42161660. doi:10.3760/cma.j.cn121090-20251125-00549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。